poisar

Stock

Rein Therapeutics, Inc. RNTX

$0.79-1.31%

Overview

RNTX market data

Price History

RNTX price chart · 1M
O
0.801900
H
0.811200
L
0.792200
C
0.792200
Vol
3,247.00
Source
US equities market feed
Observed
Aug 27, 2026, 12:00 AM
Cadence
Five-minute page cache; daily and stored hourly bars
Status
fresh

Key Stats & Performance

Open
$0.80
Previous Close
$0.80
Day High
$0.81
Day Low
$0.79
52 Week High
$1.52
52 Week Low
$0.70
7 Day Return
+1.64%
30 Day Return
+3.83%
90 Day Return
-28.63%
1 Year Return
-37.87%
Daily Notional Volume
$2.6K
Latest daily bar volume multiplied by its closing price.

Valuation & Profitability

Provider-backed
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$1.96
Diluted earnings per share over the trailing twelve months.
Beta
1.36
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
14.7%
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$0.69 – $2.18
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · market cap $67.7M · P/B 1.80.

Company News

7 captured
FDA Grants Rein Therapeutics Fast Track Designation For LTI-03Benzinga · Aug 20, 2026, 12:02 PM
HC Wainwright & Co. Reiterates Buy on Rein Therapeutics, Maintains $8 Price TargetBenzinga · Aug 18, 2026, 11:36 AM
Rein Therapeutics Q2 EPS $(0.10) Beats $(0.17) EstimateBenzinga · Aug 14, 2026, 10:47 AM
Rein Therapeutics Announces Nature Communications Publication Of First-In-Human LTI-03 Data In 24 IPF Patients, Says Drug Reduced Multiple Fibrosis And Inflammation MarkersBenzinga · Aug 4, 2026, 12:05 PM
Rein Therapeutics Begins Enrolling Patients In Phase 2 RENEW TrialBenzinga · Jul 21, 2026, 12:05 PM
Maxim Group Initiates Coverage On Rein Therapeutics with Buy Rating, Announces Price Target of $4Benzinga · Jul 20, 2026, 6:13 PM
HC Wainwright & Co. Maintains Buy on Rein Therapeutics, Lowers Price Target to $8Benzinga · Jun 1, 2026, 10:42 AM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock